IP Library Granted Patent US 11,660,343
Granted Patent B2
US 11,660,343 · App. 16/284,583 · Granted May 30, 2023

Viscosity-reducing excipient compounds for protein formulations

Inventors: David S. Soane (Palm Beach, FL); Philip Wuthrich (Watertown, MA); Rosa Casado Portilla (Middleton, MA); Robert P. Mahoney (Newbury, MA); Mark Moody (Concord, MA)
Assignee: Comera Life Sciences, Inc.
A61K47/22A61K9/0019A61K38/385A61K38/47A61K39/395A61K47/12A61K47/18A61K47/183A61K47/20A61K47/24A61K47/42A61K47/60C07K16/00C12N9/2462C12N9/96A61K39/39591C12Y302/01017
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,660,343
App. No.
16/284,583
Granted
May 30, 2023
Kind
B2
Abstract

The invention encompasses formulations and methods for the production thereof that permit the delivery of concentrated protein solutions. The inventive methods can yield a lower viscosity liquid formulation or a higher concentration of therapeutic or nontherapeutic proteins in the liquid formulation, as compared to traditional protein solutions.

Claims (19)

1. A method of reducing a viscosity of a liquid protein formulation, comprising:

preparing the liquid protein formulation comprising a therapeutic protein and a viscosity-reducing amount of caffeine, wherein (i) the liquid protein formulation contains at least about 100 mg/mL of the therapeutic protein, and (ii) the viscosity-reducing amount of caffeine is about 30 mg/ml or less,

wherein the viscosity of the liquid protein formulation is at least about 50% less than a viscosity of a control formulation, and wherein the control formulation does not contain caffeine but is otherwise identical on a dry weight basis to the liquid protein formulation.

2. The method of claim 1 , wherein the viscosity-reducing amount of caffeine is about 22 mg/ml or less.

3. The method of claim 1 , wherein the viscosity-reducing amount of caffeine is about 15 mg/ml or less.

4. The method of claim 1 , wherein the liquid protein formulation contains at least about 200 mg/ml of the therapeutic protein.

5. The method of claim 1 , wherein the liquid protein formulation contains at least about 300 mg/ml of the therapeutic protein.

6. The method of claim 1 , wherein the therapeutic protein is a therapeutic antibody.

7. The method of claim 6 , wherein the liquid protein formulation contains at least about 200 mg/ml of the therapeutic antibody.

8. The method of claim 7 , wherein the liquid protein formulation contains at least about 300 mg/ml of the therapeutic antibody.

9. The method of claim 1 , wherein the viscosity of the liquid protein formulation is at least about 70% less than the viscosity of the control formulation.

10. The method of claim 1 , wherein the viscosity of the liquid protein formulation is at least about 90% less than the viscosity of the control formulation.

11. The method of claim 1 , wherein the viscosity of the liquid protein formulation is less than about 20 cP.

12. The method of claim 11 , wherein the viscosity of the liquid protein formulation is less than about 10 cP.

13. The method of claim 1 , wherein the liquid protein formulation comprises a second viscosity-reducing excipient.

14. The method of claim 13 , wherein the second viscosity-reducing excipient is selected from the group consisting of theophylline, tyramine, procaine, lidocaine, imidazole, aspartame, saccharin, acesulfame potassium, niacinamide, and isonicotinamide.

15. The method of claim 1 , wherein the liquid protein formulation is an injectable formulation.

16. The method of claim 1 , wherein the liquid protein formulation is an aqueous formulation.

17. The method of claim 1 , wherein the viscosity-reducing amount of caffeine is about 5 mg/ml to about 15 mg/ml.

Assignments (2)
CHANGE OF NAME Recorded Feb 16, 2022
From: REFORM BIOLOGICS, INC.
To: COMERA LIFE SCIENCES, INC.
Reel/Frame 059327/0985 →
CONVERSION FROM A LIMITED LIABILITY COMPANY TO A CORPORATION Recorded Jul 7, 2021
From: REFORM BIOLOGICS, LLC
To: REFORM BIOLOGICS, INC.
Reel/Frame 056784/0447 →
Continuity (5)
Continuation 14744847 · Jun 19, 2015
Provisional Application 62136763 · Mar 23, 2015
Provisional Application 62083623 · Nov 24, 2014
Provisional Application 62014784 · Jun 20, 2014
Related Publication 20190262455A1 · Aug 29, 2019
Cited By (1)
US 12,350,340